The global retinal biologics market has experienced remarkable growth, with total revenue reaching USD 22.25 billion in 2022. This growth trajectory is projected to continue, as the market is set to reach an impressive USD 41.92 billion by 2028, fueled by a robust compound annual growth rate (CAGR) of 11.1% during the forecast period from 2022 to 2028.
Retinal biologics, a vital component of advanced ophthalmic care, are driving innovative solutions for retinal disorders, including age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. This market growth reflects the increasing prevalence of these conditions globally, advancements in biologics-based treatments, and rising investment in ophthalmic healthcare infrastructure.
Key factors contributing to this surge include:
- Rising Prevalence of Retinal Disorders: With the growing geriatric population, the demand for effective therapies for vision-threatening conditions is increasing.
- Technological Advancements: Continuous innovation in biologics and targeted therapies is enhancing treatment efficacy.
- Expanding Healthcare Access: Increasing awareness and healthcare investments, particularly in emerging markets, are broadening access to advanced retinal treatments.
Industry experts anticipate that the rapid adoption of biologics will reshape the retinal care landscape, offering significant opportunities for pharmaceutical companies, healthcare providers, and patients worldwide.
Key Takeaways: Global Retinal Biologics Market Analysis
- Market Growth Overview:
- The retinal biologics market revenue reached US$ 22.25 Billion in 2022.
- The market is projected to expand at a CAGR of 11.1% from 2022 to 2028, reaching US$ 41.92 Billion by 2028.
- Growth Drivers in the U.S.:
- Diabetic Macular Edema prevalence is a significant factor augmenting demand for retinal biologics.
- Diabetic Retinopathy is a leading cause of new blindness cases in adults aged 20–74 years in the U.S.
- Over 100 million Americans currently have diabetes or prediabetes, according to the CDC.
- Increasing R&D investments and innovative treatment strategies for diabetic macular edema are driving market growth.
- Demand Outlook in China:
- Rising prevalence of conditions such as uveitis, diabetic retinopathy, and macular degeneration.
- Lifestyle changes and unhealthy eating habits are contributing to increased diabetes cases, fueling the demand for retinal biologics.
- An aging population provides a growing target demographic for retinal treatments.
- Significant research initiatives for retinal drug development are accelerating market growth.
These insights highlight the significant growth potential in key markets such as the U.S. and China, driven by increasing prevalence of eye-related diseases, advancements in research, and a rising geriatric population.
Accelerated Market Demand: Find Comprehensive Insights and Trends in Our Full Report!
Competitive Landscape:
Numerous companies are forging licensing and collaboration agreements to extend their product reach into global markets, addressing unmet needs. Key industry players are prioritizing research and development to discover innovative medications and enhance treatment options.
For example:
In 2021, SemaThera Inc. entered into a multi-year research and licensing agreement with Roche. This partnership aims to advance SemaThera’s portfolio of novel biologics for treating ischemic retinal diseases, including diabetic retinopathy.
Key Companies Profiled:
Spark Therapeutics, Inc.; F. Hoffmann-La Roche Ltd.; Regeneron Pharmaceuticals, Inc.; AbbVie Inc.; Amgen Inc.; Novartis Pharma AG; MeiraGTx Limited; Oxurion NV; Santen Pharmaceutical Co., Ltd.; Bayer AG; Bausch Health Companies Inc.; Merck & Co., Inc.
Key Segments of Retinal Biologics Industry Survey
Retinal Biologics Market by Drug Class:
- VEGF-A Antagonists
- TNF-α Inhibitors
Retinal Biologics Market by Indication:
- Macular Degeneration
- Diabetic Macular Edema
- Diabetic Retinopathy
- Uveitis
- Others
Retinal Biologics Market by Distribution Channel:
- Institutional Sales
- Retail Pharmacies
- Mail Order Pharmacies
- Retail Sales
Retinal Biologics Market by Region:
- North America Retinal Biologics Market
- Latin America Retinal Biologics Market
- Europe Retinal Biologics Market
- East Asia Retinal Biologics Market
- South Asia & Pacific Retinal Biologics Market
- Middle East & Africa (MEA) Retinal Biologics Market
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube